Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

B. Glintborg; T. M. Kringelbach; E. Høgdall; I. J. Sørensen; D. V. Jensen; A. G. Loft; O. Hendricks; I. M. Jensen Hansen; N. Bolstad; K. Grøn; G. Eng; C. Enevold; C. H. Nielsen; D. Warren; G. Goll; J. Gehin; J. S. Johansen; M. L. Hetland

doi:10.1136/annrheumdis-2016-eular.1477

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

B. Glintborg, T. M. Kringelbach, E. Høgdall, I. J. Sørensen, D. V. Jensen, A. G. Loft, O. Hendricks, I. M. Jensen Hansen, N. Bolstad, K. Grøn, G. Eng, C. Enevold, C. H. Nielsen, D. Warren, G. Goll, J. Gehin, J. S. Johansen, M. L. Hetland

Department of Clinical Medicine

Original language	English
Article number	THU0123
Journal	Annals of the Rheumatic Diseases
Volume	75
Issue number	Suppl 2
Number of pages	1
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2016-eular.1477
Publication status	Published - 2016

Access to Document

10.1136/annrheumdis-2016-eular.1477

Cite this

Glintborg, B., Kringelbach, T. M., Høgdall, E., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Jensen Hansen, I. M., Bolstad, N., Grøn, K., Eng, G., Enevold, C., Nielsen, C. H., Warren, D., Goll, G., Gehin, J., Johansen, J. S., & Hetland, M. L. (2016). Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases, 75(Suppl 2), [THU0123 ]. https://doi.org/10.1136/annrheumdis-2016-eular.1477

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease : Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. / Glintborg, B.; Kringelbach, T. M.; Høgdall, E. et al.

In: Annals of the Rheumatic Diseases, Vol. 75, No. Suppl 2, THU0123 , 2016.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Glintborg, B, Kringelbach, TM, Høgdall, E, Sørensen, IJ, Jensen, DV, Loft, AG, Hendricks, O, Jensen Hansen, IM, Bolstad, N, Grøn, K, Eng, G, Enevold, C, Nielsen, CH, Warren, D, Goll, G, Gehin, J, Johansen, JS & Hetland, ML 2016, 'Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry', Annals of the Rheumatic Diseases, vol. 75, no. Suppl 2, THU0123 . https://doi.org/10.1136/annrheumdis-2016-eular.1477

Glintborg B, Kringelbach TM, Høgdall E, Sørensen IJ, Jensen DV, Loft AG et al. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases. 2016;75(Suppl 2):THU0123 . doi: 10.1136/annrheumdis-2016-eular.1477

@article{edff73d67eba41bca8a80ad7c32cdfb0,

title = "Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry",

author = "B. Glintborg and Kringelbach, {T. M.} and E. H{\o}gdall and S{\o}rensen, {I. J.} and Jensen, {D. V.} and Loft, {A. G.} and O. Hendricks and {Jensen Hansen}, {I. M.} and N. Bolstad and K. Gr{\o}n and G. Eng and C. Enevold and Nielsen, {C. H.} and D. Warren and G. Goll and J. Gehin and Johansen, {J. S.} and Hetland, {M. L.}",

year = "2016",

doi = "10.1136/annrheumdis-2016-eular.1477",

language = "English",

volume = "75",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease

T2 - Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

AU - Glintborg, B.

AU - Kringelbach, T. M.

AU - Høgdall, E.

AU - Sørensen, I. J.

AU - Jensen, D. V.

AU - Loft, A. G.

AU - Hendricks, O.

AU - Jensen Hansen, I. M.

AU - Bolstad, N.

AU - Grøn, K.

AU - Eng, G.

AU - Enevold, C.

AU - Nielsen, C. H.

AU - Warren, D.

AU - Goll, G.

AU - Gehin, J.

AU - Johansen, J. S.

AU - Hetland, M. L.

PY - 2016

Y1 - 2016

U2 - 10.1136/annrheumdis-2016-eular.1477

DO - 10.1136/annrheumdis-2016-eular.1477

M3 - Conference abstract in journal

SN - 0003-4967

VL - 75

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - THU0123

ER -